登革热在人类中的严重程度因日本脑炎病毒免疫力的减弱而增强

IF 14.6 1区 医学 Q1 CELL BIOLOGY
Sidharth Malhotra, Birendra P. Gupta, Surendra Uranw, Chinmay Kumar Mantri, Abhay P.S. Rathore, Ashley L. St. John
{"title":"登革热在人类中的严重程度因日本脑炎病毒免疫力的减弱而增强","authors":"Sidharth Malhotra,&nbsp;Birendra P. Gupta,&nbsp;Surendra Uranw,&nbsp;Chinmay Kumar Mantri,&nbsp;Abhay P.S. Rathore,&nbsp;Ashley L. St. John","doi":"10.1126/scitranslmed.ads9572","DOIUrl":null,"url":null,"abstract":"<div >Owing to increased global movement, vector-spread permissive climate change, and increased vaccination coverage against certain flaviviruses, the likelihood of being exposed to multiple flaviviruses in a lifetime has increased. Although many Asian countries have routine vaccination campaigns against Japanese encephalitis virus (JEV), the effect of JEV immunity on dengue disease severity is largely unknown. Here, we aimed to understand the effect of preexisting immunity against JEV on subsequent dengue disease outcomes in a prospective human cohort in Nepal, which has a high prevalence of JEV immunity and rapidly rising dengue virus (DENV) infections. A cohort consisting of 546 participants was studied over three dengue seasons and 5 years. Chymase, a serum biomarker of severe dengue across multiple patient cohorts, was assessed alongside clinical outcomes to determine whether there were associations between JEV immunity and dengue severity. We observed that midrange neutralizing antibody titers, approximately a 1:160 serum dilution capable of inhibiting JEV, were associated with heightened biomarkers of dengue disease severity and warning signs of severe disease in this cohort of patients who were mostly experiencing primary dengue infections. These results suggest that waning immunity to JEV could enhance the severity of dengue disease. This highlights the potential of maintaining strong immunity to JEV through vaccine boosters, not only to maintain protection against JEV in endemic regions but also to limit the potential of antibody-mediated enhancement of dengue disease.</div>","PeriodicalId":21580,"journal":{"name":"Science Translational Medicine","volume":"17 814","pages":""},"PeriodicalIF":14.6000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dengue disease severity in humans is augmented by waning Japanese encephalitis virus immunity\",\"authors\":\"Sidharth Malhotra,&nbsp;Birendra P. Gupta,&nbsp;Surendra Uranw,&nbsp;Chinmay Kumar Mantri,&nbsp;Abhay P.S. Rathore,&nbsp;Ashley L. St. John\",\"doi\":\"10.1126/scitranslmed.ads9572\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div >Owing to increased global movement, vector-spread permissive climate change, and increased vaccination coverage against certain flaviviruses, the likelihood of being exposed to multiple flaviviruses in a lifetime has increased. Although many Asian countries have routine vaccination campaigns against Japanese encephalitis virus (JEV), the effect of JEV immunity on dengue disease severity is largely unknown. Here, we aimed to understand the effect of preexisting immunity against JEV on subsequent dengue disease outcomes in a prospective human cohort in Nepal, which has a high prevalence of JEV immunity and rapidly rising dengue virus (DENV) infections. A cohort consisting of 546 participants was studied over three dengue seasons and 5 years. Chymase, a serum biomarker of severe dengue across multiple patient cohorts, was assessed alongside clinical outcomes to determine whether there were associations between JEV immunity and dengue severity. We observed that midrange neutralizing antibody titers, approximately a 1:160 serum dilution capable of inhibiting JEV, were associated with heightened biomarkers of dengue disease severity and warning signs of severe disease in this cohort of patients who were mostly experiencing primary dengue infections. These results suggest that waning immunity to JEV could enhance the severity of dengue disease. This highlights the potential of maintaining strong immunity to JEV through vaccine boosters, not only to maintain protection against JEV in endemic regions but also to limit the potential of antibody-mediated enhancement of dengue disease.</div>\",\"PeriodicalId\":21580,\"journal\":{\"name\":\"Science Translational Medicine\",\"volume\":\"17 814\",\"pages\":\"\"},\"PeriodicalIF\":14.6000,\"publicationDate\":\"2025-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Science Translational Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.science.org/doi/10.1126/scitranslmed.ads9572\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Science Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.science.org/doi/10.1126/scitranslmed.ads9572","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

由于全球流动的增加、媒介传播的有利气候变化以及针对某些黄病毒的疫苗接种覆盖率的提高,一生中接触多种黄病毒的可能性增加了。尽管许多亚洲国家开展了针对日本脑炎病毒(JEV)的常规疫苗接种运动,但JEV免疫对登革热严重程度的影响在很大程度上是未知的。在尼泊尔,我们的目的是了解先前存在的对乙脑病毒的免疫对随后登革热疾病结局的影响,尼泊尔乙脑病毒免疫高发,登革热病毒(DENV)感染迅速上升。在3个登革热季节和5年期间,对546名参与者进行了队列研究。Chymase是多个患者队列中严重登革热的血清生物标志物,与临床结果一起评估,以确定乙脑病毒免疫与登革热严重程度之间是否存在关联。我们观察到,中等中和抗体滴度,大约1:160的血清稀释度能够抑制乙脑病毒,与登革热疾病严重程度的生物标志物升高和该队列中主要经历原发性登革热感染的严重疾病警告信号相关。这些结果表明,对乙脑病毒免疫力的减弱可能会增加登革热的严重程度。这突出了通过疫苗增强剂维持对乙脑病毒的强免疫力的潜力,不仅可以在流行地区维持对乙脑病毒的保护,而且还可以限制抗体介导的登革热疾病增强的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Dengue disease severity in humans is augmented by waning Japanese encephalitis virus immunity
Owing to increased global movement, vector-spread permissive climate change, and increased vaccination coverage against certain flaviviruses, the likelihood of being exposed to multiple flaviviruses in a lifetime has increased. Although many Asian countries have routine vaccination campaigns against Japanese encephalitis virus (JEV), the effect of JEV immunity on dengue disease severity is largely unknown. Here, we aimed to understand the effect of preexisting immunity against JEV on subsequent dengue disease outcomes in a prospective human cohort in Nepal, which has a high prevalence of JEV immunity and rapidly rising dengue virus (DENV) infections. A cohort consisting of 546 participants was studied over three dengue seasons and 5 years. Chymase, a serum biomarker of severe dengue across multiple patient cohorts, was assessed alongside clinical outcomes to determine whether there were associations between JEV immunity and dengue severity. We observed that midrange neutralizing antibody titers, approximately a 1:160 serum dilution capable of inhibiting JEV, were associated with heightened biomarkers of dengue disease severity and warning signs of severe disease in this cohort of patients who were mostly experiencing primary dengue infections. These results suggest that waning immunity to JEV could enhance the severity of dengue disease. This highlights the potential of maintaining strong immunity to JEV through vaccine boosters, not only to maintain protection against JEV in endemic regions but also to limit the potential of antibody-mediated enhancement of dengue disease.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Science Translational Medicine
Science Translational Medicine CELL BIOLOGY-MEDICINE, RESEARCH & EXPERIMENTAL
CiteScore
26.70
自引率
1.20%
发文量
309
审稿时长
1.7 months
期刊介绍: Science Translational Medicine is an online journal that focuses on publishing research at the intersection of science, engineering, and medicine. The goal of the journal is to promote human health by providing a platform for researchers from various disciplines to communicate their latest advancements in biomedical, translational, and clinical research. The journal aims to address the slow translation of scientific knowledge into effective treatments and health measures. It publishes articles that fill the knowledge gaps between preclinical research and medical applications, with a focus on accelerating the translation of knowledge into new ways of preventing, diagnosing, and treating human diseases. The scope of Science Translational Medicine includes various areas such as cardiovascular disease, immunology/vaccines, metabolism/diabetes/obesity, neuroscience/neurology/psychiatry, cancer, infectious diseases, policy, behavior, bioengineering, chemical genomics/drug discovery, imaging, applied physical sciences, medical nanotechnology, drug delivery, biomarkers, gene therapy/regenerative medicine, toxicology and pharmacokinetics, data mining, cell culture, animal and human studies, medical informatics, and other interdisciplinary approaches to medicine. The target audience of the journal includes researchers and management in academia, government, and the biotechnology and pharmaceutical industries. It is also relevant to physician scientists, regulators, policy makers, investors, business developers, and funding agencies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信